Episode description (with key takeaways)This episode tackles sulfonamides, trimethoprim–sulfamethoxazole, quinolones, and urinary-tract–focused agents as the pharmacology of broad reach. These drugs are versatile, familiar, and effective-precisely why they demand disciplined use. We explore folate pathway inhibition, DNA gyrase/topoisomerase targeting, tissue penetration, and urinary concentration to show how broad activity can both solve problems and create new ones. The clinical thread is judgement: choosing reach without recklessness.

Key takeaways to sharpen practice:

* Mechanistic breadth: folate antagonism vs DNA topology disruption.

* PK advantage: tissue and urinary penetration as therapeutic leverage.

* Resistance cost: selection pressure and class-wide consequences.

* Safety signals: hypersensitivity, QT effects, tendinopathy, dysglycaemia.

* Indication discipline: when “broad” is appropriate-and when it is not.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe